Hypertension – Antenatal, Intrapartum and Postpartum

Document Type | Guideline
--- | ---
Function(s) | Clinical Service Delivery
Directorates | Women’s Health
Department(s) affected | Maternity
Patients affected (if applicable) | All patients in Maternity
Staff members affected | All clinicians in Maternity
Key words | Hypertension, pre eclampsia,
Author – role only | Maternal Fetal Medicine (MFM) consultant
Owner (see ownership structure) | Owner: Service Clinical Director – Secondary Maternity Services
Edited by | Clinical Policy Advisor
Date first published | May 2009
Date this version published | January 2017 - reviewed
Review frequency | 3 yearly
Unique Identifier | NMP200/SSM/074

Contents

1. **Purpose of guideline**
2. **Guideline management principles and goals**
3. **Definitions**
4. **Summary table**
5. **Pre-pregnancy care**
   a) **Management of chronic hypertension**
   b) **Prevention and prediction of pre-eclampsia**
6. **General antenatal care**
7. **Antenatal management of chronic hypertension**
8. **Antenatal monitoring in pre-eclampsia**
9. **Antenatal therapy in pre-eclampsia and hypertension**
10. **Management in labour**
11. **Severe pre-eclampsia**
12. **Acute management of hypertension**
13. **Anaesthesia and analgesia for women with pre-eclampsia and hypertension**
14. **Criteria for transfer to critical care**
15. **Postpartum management**
16. **What to do before developing an antenatal care plan**
17. **What to do after the risk assessment**
18. **Supporting evidence**
19. **Associated ADHB documents**
20. **Disclaimer**
21. **Corrections and amendments**
1. Purpose of guideline

This guideline describes evidence based care for women with background hypertension and pre-eclampsia for clinicians within Auckland District Health Board (ADHB).

2. Guideline management principles and goals

Pre-eclampsia complicates 2 - 3% of all pregnancies (5 - 7% of nulliparous women) and 2% of women with pre-eclampsia develop eclampsia. A priority of antenatal care in the second half of pregnancy is to detect the development of pre-eclampsia. When pre-eclampsia develops, delivery of the baby and placenta is the only cure. Management is aimed at timing delivery to prevent maternal complications whilst minimising fetal morbidity and mortality from prematurity and associated intrauterine growth restriction.

3. Definitions

SBP = systolic blood pressure  
DBP = diastolic blood pressure  
PCR = protein creatinine ratio  
MFM = maternal fetal medicine

Hypertension is a blood pressure SBP ≥ 140 and/or DBP ≥ 90 mmHg on two or more consecutive occasions at least 4 hours apart or one measurement SBP ≥ 170 and or DBP ≥ 110 mmHg.

Women with an increment of > = 30 mmHg systolic and/or > = 15 mmHg diastolic but not at the levels above do not meet the definition of hypertension, however, such women should be monitored more closely.

Severe hypertension is a SBP ≥ 170 and or DBP ≥110 mmHg on one occasion at any time.

Proteinuria for definition of pre-eclampsia is a PCR ≥ 30 on a spot urine sample, ≥ 2+ on two separate dipstick measures or a 24 hour collection ≥ 0.3g in 24 hours. Because of the close correlation between spot urine PCR and 24 hour urine, the latter is rarely required (SOMANZ). Repeated quantitative estimations of proteinuria may be of value in assessing disease progression however neither the rate of increase nor the amount of proteinuria affects maternal or perinatal outcome.

Pre-eclampsia is when hypertension arises after 20 weeks gestation and is accompanied by one of more of the following: (SOMANZ)
Renal involvement:

- Significant proteinuria – dipstick proteinuria subsequently confirmed by spot urine protein/creatinine ratio ≥ 30mg/mmol. In view of the close correlation between spot urine protein/creatinine ratio and 24 hour urine excretion, the latter is rarely required (21)
- Serum or plasma creatinine > 90 μmol/L
- Oliguria

Haematological involvement:

- Thrombocytopenia
- Haemolysis
- Disseminated intravascular coagulation

Liver involvement:

- Raised serum transaminases
- Severe epigastric or right upper quadrant pain

Neurological involvement:

- Convulsions (eclampsia)
- Hyporeflexia with sustained clonus
- Severe headache
- Persistent visual disturbances (photopsia, scotomata, cortical blindness, retinal vasospasm)
- Stroke

Also:

- Pulmonary oedema
- Fetal growth restriction
- Placental abruption
4. Summary table

<table>
<thead>
<tr>
<th>Problem</th>
<th>Recommended Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Background Hypertension or Previous PET</strong></td>
<td>• Review cause and effect&lt;br&gt;• Refer MFM if severe HT or previous early onset preeclampsia ≤ 30 weeks&lt;br&gt;• Consider prophylaxis with Aspirin/Calcium&lt;br&gt;• Coordinate more frequent antenatal reviews&lt;br&gt;• Regular fetal growth assessment (monthly if uncomplicated, more frequently if additional clinical concerns)</td>
</tr>
<tr>
<td><strong>Antenatal Hypertension</strong></td>
<td>• Review cause and effect&lt;br&gt;• Consider treatment if SBP ≥ 140 - 160 and or DBP ≥ 95 - 100 consistently&lt;br&gt;• Discuss case with obstetric senior clinical staff member (obstetrician +/- Physician) and MFM as appropriate (especially if ≤ 30 weeks)</td>
</tr>
<tr>
<td><strong>Hypertension in Labour</strong></td>
<td>• Review cause and effect&lt;br&gt;• Consider treatment if SBP ≥ 160 and or DBP ≥ 100 or if symptomatic in women with previously lower booking blood pressure&lt;br&gt;• See Hypertension in Labour – Management for recommended medications&lt;br&gt;• Consider use of epidural&lt;br&gt;• Consider use of magnesium sulphate (see ‘Associated ADHB documents’ section below for guideline)&lt;br&gt;• Discuss with obstetric senior clinical staff member (obstetrician +/- Physician) and MFM as appropriate (especially if ≤ 30 weeks)</td>
</tr>
<tr>
<td><strong>Eclampsia</strong></td>
<td>• Use ABC for immediate resuscitation&lt;br&gt;• See ‘Associate ADHB documents’ section below for magnesium sulphate guideline&lt;br&gt;• Seek advice, support and High Dependency Unit (HDU) care (see below)&lt;br&gt;• Recommended total fluid rate = 85mls/hour</td>
</tr>
<tr>
<td><strong>Post Natal Hypertension</strong></td>
<td>• Review cause and effect&lt;br&gt;• Consider treatment if SBP &gt; 160 and or DBP &gt; 100 consistently&lt;br&gt;• Definitely treat if SBP &gt; 170, DBP &gt; 110 consistently&lt;br&gt;• Consider magnesium sulphate especially within 48 hours of delivery (see ‘Associated ADHB documents’ section below for guideline)&lt;br&gt;• Discuss case with senior clinical staff member and MFM if additional concerns</td>
</tr>
</tbody>
</table>
5. Pre-pregnancy care

Hypertension arising before pregnancy or detected in the first 20 weeks of pregnancy implies long-standing or chronic hypertension. The majority of these women have essential hypertension with no underlying renal or adrenal cause however should be referred for medical opinion early in pregnancy. Very rarely pre-eclampsia may present before 20 weeks often in the context of an abnormal foetus/baby or severe maternal disease and usually with abnormal indices of utero placental circulation.

a) Management of chronic hypertension

Other causes of chronic hypertension should always be considered e.g. renal disease, phaeochromocytoma, Cushing’s syndrome, Conn’s syndrome, coarctation of aorta.

Hypertension should ideally be controlled before conception. Specific consideration should be given to the choice of anti-hypertensive in women who may become pregnant. For those women with complicated pre-existing hypertension (including those on more than one antihypertensive agent) we would recommend preconception referral for obstetric physician review and discussion. Currently it seems reasonable to continue ACE inhibitors before pregnancy especially in women with specific indications (i.e. diabetic nephropathy) but with specific instructions to stop these as soon as pregnancy is suspected and to then attend for medical review.

Methyldopa remains the first drug of choice for the longer term treatment in pregnancy. Alternatives (listed in order of published data including safety data; most extensive data first) include labetalol, slow-release nifedipine, and metoprolol. ACE inhibitors, diuretics and atenolol should be avoided due to potential fetal side effects (see Antenatal Management of Chronic Hypertension).
b) Prevention and prediction of pre-eclampsia

Prediction

Currently pre-eclampsia cannot be reliably predicted or prevented although various risk factors have been identified which may be present at antenatal booking (SOMANZ).

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Relative risk [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous history of pre-eclampsia</td>
<td>7.19 [5.85,8.83]</td>
</tr>
<tr>
<td>Antiphospholipid antibodies</td>
<td>9.72 [4.34,21.75]</td>
</tr>
<tr>
<td>Pre-existing diabetes</td>
<td>3.56 [2.54,4.99]</td>
</tr>
<tr>
<td>Multiple pregnancy</td>
<td>2.91 [2.04, 4.21]</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>2.91 [1.28, 6.61]</td>
</tr>
<tr>
<td>Family history of pre-eclampsia</td>
<td>2.90 [1.70, 4.93]</td>
</tr>
<tr>
<td>Elevated BMI &gt; 25</td>
<td>2.47 [1.66, 3.67]</td>
</tr>
<tr>
<td>Maternal age ≥ 40</td>
<td>1.96 [1.34, 2.87]</td>
</tr>
<tr>
<td>Diastolic BP ≥ 80 mmHg at booking</td>
<td>1.38 [1.01, 1.87]</td>
</tr>
</tbody>
</table>

A number of other factors are also associated with an increased risk of preeclampsia including chronic hypertension, pre-existing renal disease, autoimmune disease, > 10 years since previous pregnancy, short sexual relationship prior to conception, other thrombophilias e.g. Factor V Leiden and possibly periodontal disease.

Low dose aspirin (LDA)

LDA (100mg daily) initiated early in pregnancy reduces the overall risk of pre-eclampsia by about 15% with a similar reduction in perinatal death. Prophylactic use in pregnancy should be considered in women with an increased risk of pre-eclampsia as above.

Calcium

Women with low calcium intake (< 600mg/day or ≤ 2 portions or cups of calcium rich foods) should be offered prophylaxis with calcium supplements of 1 – 1.5 g daily of elemental calcium (calcium carbonate 1.25 g contains 500mg of elemental calcium) as this reduces the risk of preeclampsia by about 60% (RR 0.36 (0.18 - 0.70)). Calcium rich foods are mainly dairy products including: yoghurt (not low fat), milk (any fat and including flavoured milk), and cheese (25g = 200mg calcium). Calcium in smaller amounts is also available in deep green leafy vegetable, fish with edible bones, tofu made with calcium, legumes and foods fortified with calcium (Villar 2006). Women at very high risk of preeclampsia also benefit from calcium supplement [RR 0.22 (0.12 - 0.47)]. The doses above refer to elemental calcium (Cochrane library).
Low dose pregnancy multivitamin/folic acid

Preliminary evidence suggests that low dose pregnancy multivitamins containing folic acid may also reduce the risk of preeclampsia (Wen 2008, Bodnar 2006). Note high dose vitamin C and vitamin E are not of benefit in reducing preeclampsia and may be harmful (Poston, 2006).

Antenatal visits

The frequency of antenatal visits to check blood pressure and urine should be increased in women with two or more risk factors (PRECOG). These women may be eligible to visit the Day Assessment Unit (DAU) rather than be admitted to the antenatal or other ward.

Admission - Day Assessment Unit: please see the Associated ADHB document section below.

Severe or atypical disease

For advice on the management of women with a history of particularly severe or atypical disease contact the MFM consultant or an obstetric physician. Women with a past history of severe pre-eclampsia (complicated or leading to delivery before 32 weeks) should be referred to MFM consultant care in the first trimester and have at least fortnightly BP and urine checks after 20 weeks. The APEC leaflet is a useful resource of information for these women.

6. General antenatal care

Patient information

Each woman should be informed verbally by her lead maternity carer (LMC) at booking and given written information about the symptoms and signs of pre-eclampsia and the reasons why BP and urine are checked at each visit (APEC leaflet).

Maternal Fetal Medicine Referral – please see Associated ADHB document section below.

Taking the blood pressure (ASSHP, SOMANZ)

i  Use a mercury sphygmomanometer;
ii  Use the correct cuff - if the arm circumference > 33 cm use a large cuff;
iii  Keep the cuff at the level of heart;
iv  Use a seated position with feet supported;
v  By convention the right arm is usually used to reduce observer error;
vi  Record the exact reading i.e. 128/88, not 130/90;
vii  Deflate the cuff slowly at approximately 2 mmHg per second;
viii Use Korotkoff 5 or K5 (disappearance of sounds) not K4 (muffling), unless sounds are heard to zero when K4 should be used;
ix Automated blood pressure monitors can significantly underestimate the blood pressure in pre-eclampsia. It is recommended that automated blood pressure values should be compared with conventional sphygmomanometery at admission or at the beginning of treatment.

Day Assessment Unit (DAU)

Referral to the DAU for further assessment and investigation should be considered when there is a suspected hypertensive disorder of pregnancy, and there is a need for visits outside the weekly clinic setting. DAU is open 5 days a week and is established for women to improve continuity of care, improve psychological well being, reduce disruption to family life and reduce inpatient stays. This model of care has been proven to be successful and safe and may improve outcomes for the women. When referring to DAU please use the referral form in the clinical areas and ensure a member of the clinical team has been identified who is contactable and will be responsible for the care on DAU.

Admission - Day Assessment Unit: please see the Associated ADHB document section below.

Inpatient admission

Criteria for recommending inpatient admission for assessment include:

- Symptoms egg headaches, visual disturbance or epigastric pain
- Proteinuria ≥ 1+ with hypertension
- SBP ≥ 160 and or DBP > 100
- Abnormal blood results: falling or low platelets < 150, rising urate, raised creatinine (abnormal if > 80µmol/L), raised ALT, AST (abnormal if > 40iu) or raised bilirubin (abnormal if >)
- Antepartum haemorrhage
- Reduced fetal movements
- Uterine activity

Outpatient care

In later pregnancy women with hypertension in the absence of proteinuria (gestational hypertension or pregnancy induced hypertension) and with normal blood tests or uncomplicated pre-eclampsia without symptoms may be managed on an outpatient basis. This should be coordinated by a consistent senior medical team member. Careful surveillance for the development of pre-eclampsia or complications (including fetal) should continue as the development of these substantially increases the risks to mother and baby. This usually entails 2 or 3 clinical assessments per week. We recommend that where outpatient review is considered that this should occur in clinic or the day assessment unit as appropriate (See also details in DAU). Delivery should be in a secondary or tertiary unit.
All women managed as an outpatient should be told and understand the symptoms and signs of concern. Outpatient management of uncomplicated disease does not alter the clinical outcome but improves the satisfaction with shorter inpatient stays.

**Fulminating pre-eclampsia**

Women with fulminating pre-eclampsia (usually with severe hypertension (SBP > 170 and or DBP > 110) with or without symptoms) require urgent admission to hospital, accompanied by a doctor or midwife. It is important to discuss the admission with the on call labour ward specialist/SMO and on call MFM team.

**Bed rest**

For mild hypertension in pregnancy in a home or hospital setting has not been shown to be beneficial and may be harmful, potentially increasing the risk of venous thromboembolism.
7. Antenatal management of chronic hypertension

Normal BP profile in pregnancy

BP decreases in normal pregnancy, reaching its lowest at 20 weeks before rising to pre-pregnant levels or slightly higher at term. Similar changes are often seen in chronic hypertension and therefore anti-hypertensive therapy may need to be reduced or discontinued in early pregnancy.

Threshold for treatment

Anti-hypertensive therapy for mild chronic hypertension decreases the incidence of severe hypertension but the impact on perinatal outcome is unclear. There is insufficient evidence on which to base recommendations regarding thresholds for treatment. Anti-hypertensive drugs may be initiated or increased when the BP is consistently above SBP ≥ 140 - 160 and or DBP ≥ 95 - 100. Treatment targets should be individualized but in general we would recommend SBP 140 - 160 and DBP 90 - 100.

Medications

If conception occurs on ACE inhibitors, diuretics or atenolol, anti-hypertensive therapy should be changed or stopped if not required as soon as possible. We recommend a preparation with a better safety history in pregnancy (usually methyldopa) (see Antenatal Therapy in Pre-Eclampsia & Hypertension). Discussion with MFM/obstetric physician including consideration of a MFM clinic review is usually indicated.

Super-imposed pre-eclampsia

Women with chronic hypertension are at increased risk of super-imposed pre-eclampsia and require careful assessment if there is an apparent rise in BP or the development of proteinuria.

Back to Contents
8. Antenatal monitoring in pre-eclampsia

Several points are worth emphasising:

- Severe PET and eclampsia are life-threatening conditions; the labour and birthing suite (L&B) registrar on call should always inform and involve the on call SMO (+/- obstetric physician) and the anaesthetist. A plan of management should be made and written in the patient’s clinical record. The duty paediatrician should also be informed if preterm delivery is expected.
- Pre-eclampsia is a multisystem disease, where each end-organ (e.g. blood vessels, kidney, CNS, liver, clotting system and placenta) may be affected to a greater or lesser extent. Careful assessment of each end organ is essential for optimal management.
- Pre-eclampsia progresses at different rates in different cases; occasionally the rate of progress can be remarkably rapid. Eclampsia rarely occurs without premonitory symptoms (e.g. severe headache, visual disturbance, epigastric pain) and symptoms should always be taken seriously.
- Hypertension is a treatable manifestation of pre-eclampsia. Reducing high blood pressure will not alter the underlying progression of the disease although in the short term it may reduce the risk of eclampsia and a cerebrovascular accident.
- The L&B registrar on call must be informed if any woman has SBP ≥ 170 and or DBP ≥ 110, which has not fallen below these levels on rechecking 20 minutes later.
- The registrar on call will be responsible for instituting appropriate antihypertensive treatment, with supervision from the relevant SMO. (See Acute Management of Hypertension below).
- Women whose condition is difficult to control, or who may have renal or hepatic involvement should be discussed urgently with the relevant SMO an MFM/obstetric physician on call for delivery unit.
- 40% of eclamptic seizures occur after delivery thus, post-natal vigilance is essential, although the disease will resolve spontaneously in all but a few cases.

Remember ECLAMPSIA can occasionally occur in the absence of hypertension or proteinuria.

Assessment, physical signs and monitoring

These should be documented in the patient’s clinical record. The development of hepatic tenderness, hyperreflexia ± clonus, breathing difficulties, abdominal pain, antepartum haemorrhage or altered fetal movements are an indication for urgent senior review.

Daily assessment of maternal and fetal condition is required at registrar level or above to determine that conservative management, rather than delivery, is safe and can be continued.

Assessment should include systematic review of the mother for symptoms and signs that indicate severe pre-eclampsia including:

- Persistent severe hypertension (SBP ≥ 170 and or, DBP ≥ 110)
• Oliguria less than 100 mls/4 hours
• Oliguria less than 500 mls/24 hours
• Serum creatinine > 0.90 µmol/L
• Signs of neurological involvement (persistent headache, visual disturbance, Hyperreflexia with clonus)
• Pulmonary oedema
• Liver dysfunction (abdominal pain with abnormal LFTs)
• Haematological involvement (thrombocytopenia < 100 or falling platelets, DIC
• Assessment should also include systematic review of the foetus including:
  - Fetal well being (movements, CTG, ultrasound and Doppler assessments)
  - Signs of placental abruption (vaginal bleeding, uterine contractions or irritability, abdominal discomfort or pain)

Maternal monitoring

Recommended standards for inpatient maternal monitoring include:

• 4-6 hourly BP (except overnight when an interval of 8 hours is acceptable, provided the BP is < 160/100 on retiring)
• Daily urinalysis
• MSU (at least one)
• Twice weekly full blood count (including haemoglobin, platelet count), creatinine, uric acid, liver function tests (albumin, ALT and AST)
• Coagulation studies should be performed if falling platelets (< 100) or abnormal liver tests or concern about possible placental abruption
• Laboratory investigations should be repeated more often if there are concerns about either the maternal or fetal condition

Flowcharts

The rates of change in the various indices used to monitor pre-eclampsia may be more useful than the absolute levels. The use of the result flowcharts for recording maternal observations and laboratory results makes the identification of adverse trends more readily identifiable and is recommended.

Fluid balance

Women with pre-eclampsia are generally hypovolaemic but their tissues are fluid overloaded. Specific attention should be paid to fluid balance, which should be closely monitored if there are concerns about rapidly accumulating oedema, rapidly increasing proteinuria, reduced urine output or rising urea/creatinine.

Fetal assessment

As a minimum should include fortnightly:

• Growth measurements
• Amniotic fluid volume estimates
• Umbilical artery Doppler studies
More frequent ultrasound assessment including Doppler studies may be required especially in severe or complicated disease

**Umbilical artery Doppler**

The frequency of umbilical artery Doppler studies and liquor volume assessment may need to be increased if either are abnormal or in the presence of IUGR (AC < 10% or EFW < 10% on customised charts or reduced growth velocity). Consider discussion with MFM if there are additional concerns.

**CTG monitoring**

Inpatient daily CTGs are recommended for all foetuses considered viable and not before 24 weeks. The timing of ‘viability’ at early gestations can be very complex and should ideally involve a multidisciplinary approach and include careful discussion with the parents by the MFM team and Neonatologist. Outpatient CTGs will depend on the severity of condition including ultrasound findings.

**Neonatal Review**

Referral for expert neonatal opinion should always be considered but especially when early delivery before 30 weeks is possible. Ideally referral would be made at a consultant/specialist level. The on call neonatal specialist can be contacted via switchboard.

Back to Contents
9. Antenatal therapy in pre-eclampsia and hypertension

Disease progress

It should be stressed that anti-hypertensive therapy does not prevent the progression of the underlying disease process and close maternal and fetal surveillance should be continued.

Corticosteroids

For women with confirmed pre-eclampsia a two-dose course of corticosteroid (betamethasone 11.4 mg with a repeat dose of betamethasone 11.4 mg after 24 hours) should be administered if delivery is likely to be necessary between 24 and 34 weeks gestation. If the woman remains undelivered more than 7 days after administration of the first course of steroids consideration should be given to repeating a single injection of betamethasone (11.4mg) at weekly intervals until 32 completed weeks. Further consideration should also be given to corticosteroids if elective caesarean delivery is planned between 34 and 38 weeks.

Monitoring of maternal blood sugars maybe indicated when weekly steroids administration is undertaken. The physician should be informed of any known diabetic receiving antenatal steroids.

Magnesium sulphate for neuroprotection should be considered when a decision to deliver at less than 30 weeks gestation is made (see the Associated ADHB document section below).

Threshold for anti-hypertensive therapy

Compared to no treatment, anti-hypertensive therapy for mild to moderate hypertension decreases the incidence of severe hypertension, the need for additional anti-hypertensives and the presence of proteinuria at delivery, regardless of drug used (Magee 1999). However the overall impact on perinatal outcomes is unclear.

Anti-hypertensive drugs should be considered when the BP is consistently above SBP $\geq$ 140 - 160 and or DBP $\geq$ 95 - 100 consistently and would not generally be required at lower levels.

Which anti-hypertensive

There is no clear evidence that one particular drug is better than any other. The choice of anti-hypertensive should depend on the experience and familiarity of the individual clinician and should include current knowledge of adverse maternal and fetal side effects.

For long term therapy (listed in order of international experience and extent of published safety data):
• Methyldopa: start at 250mg tds, increasing to a maximum of 3g daily
• Labetalol: with food. Start 100mg bd increasing to 200 - 400mgs bd; maximum dose 2g daily (in three divided doses daily).
• Nifedipine slow-release: start 20mg SR bd; or 30 - 60mg nifedipine long-acting once a day
• Sublingual nifedipine is not recommended in any instance for the reduction of BP
• Oral immediate release nifedipine is not recommended for long term treatment
• Metoprolol: start 47.5mg CR bd, increasing to 95mg CR bd

Pre-eclampsia at term (≥ 37 weeks)

This is generally an indication for delivery. Oral treatment should continue through labour. Stabilisation of blood pressure with oral treatment before induction of labour or caesarean section will help avoid the need for parenteral therapy. An epidural has a beneficial effect on hypertension occurring during labour and should be discussed and recommended prior to labour and or delivery.

Early onset and/or severe pre-eclampsia

A discussion with and referral to MFM/obstetric physician is strongly recommended (i.e. less than 30 weeks gestation or pre-eclampsia complicated by disseminated intravascular coagulopathy (DIC), HELLP (haemolysis, elevated liver enzymes & low platelet count) or multisystem derangement. All women with early onset severe pre-eclampsia or complicated disease should have careful postnatal follow up and review after hospital discharge. We recommend this should be by the obstetric physicians and/or MFM team.

Maternal Fetal Medicine Referral: See the Associated ADHB document section below.

Seizures

• All cases of unexpected seizures in pregnant women should be assumed to be eclampsia until proven otherwise. The mother should be stabilised and transferred to the High Dependency Unit (HDU). Magnesium sulphate IV should be given for prevention of recurrent seizures (see ‘Associated ADHB documents’ section below for magnesium sulphate guideline).
10. Management in labour

Investigations

- Urinary protein (dipstick and spot protein/creatinine ratio)
- MSU
- FBC
- Coagulation screen - if platelets falling rapidly or < 100 or signs of haemolysis
- Creatinine (abnormal if > 80 µmol/l)
- Serum ALT and AST (abnormal if > 40iu)

Decision to deliver

The decision to deliver will usually be taken by a specialist obstetric consultant. Pre-eclampsia on its own is not an indication for caesarean delivery. Consideration should be given to the usual obstetric parameters of achieving safe vaginal delivery within a reasonable time. Epidural analgesia for women with pre-eclampsia is generally recommended as long as there is no coagulopathy. Remember that stabilisation of the maternal condition first will lead to a safer delivery by whatever route.

Threshold for treatment

Again this should be individualised however, the previously discussed levels of BP are reasonable to use in labour (SBP 140 - 160 and or DBP 95 - 100). Treatment options are outlined in Acute Management of Hypertension.

11. Severe pre-eclampsia

Severe pre-eclampsia is defined as pre-eclampsia with any of the following:

- Persistent severe hypertension (SBP ≥ 170 and or DBP ≥ 110)
- Oliguria less than 100 ml/4 hours
- Oliguria less than 500 ml/24 hours
- Serum creatinine > 0.90 µmol/L
- Signs of neurological involvement (see ‘Associated ADHB documents’ section below for magnesium sulphate guideline)
- Pulmonary oedema
- Liver dysfunction (abdominal pain with abnormal LFTs)
- Haematological involvement (thrombocytopenia < 100 or rapidly falling platelets, DIC)

Overall management

This is aimed at stabilising the maternal condition and timely delivery with continued postnatal care and appropriate follow up. Early transfer to a tertiary centre is recommended for women with early onset pre-eclampsia to avoid the adverse
outcomes associated with the transfer of a critically ill mother or preterm neonate. In severe hypertension (SBP ≥ 170 and or DBP ≥ 110) anti-hypertensive therapy is urgently required to reduce the risk of maternal intracerebral haemorrhage. Senior clinicians should be involved directly in managing the mother and transfer to HDU or an area with 1:1 midwifery or nursing care is strongly recommended. Fetal monitoring throughout is strongly recommended.

Anaesthetic involvement

The senior anaesthetist on call for labour and birthing suite should be involved early in the management plan and process. These women should be ‘specialled’ on a one-to-one basis by an experienced midwife ideally on the HDU. If the HDU is full or there are insufficient staffing numbers or experience these women should be transferred to other high care areas (e.g. level 8 DCCM). An intensive therapy monitoring chart should be used to record observations.

Fluid management and urinary output

Whilst pre-eclampsia and especially severe pre-eclampsia is a condition with reduced intravascular volume the associated endothelial dysfunction means that fluid typically leaks more quickly from the vascular space into surrounding tissue and compartments (dependent oedema, ascites, pulmonary oedema, pleural and pericardial effusions, cerebral oedema etc). Because of this it is essential that strict attention is paid to fluid balance. Usually these women are managed with the fluid restriction (typically 85 mls/hour, 1000mls over 12 hours) though limited fluid challenges may be indicated in exceptional circumstances.

Urinary output

This should be measured on an hourly basis however it is reasonable to use a definition of oliguria of less than 100 mls over four hours before intervention is considered especially fluid challenge in the oedematous mother. Mildly elevated serum creatinine is a reflection of the depleted intravascular volume and renal involvement. In nearly all cases the apparent renal impairment will reverse completely after delivery and as the pre-eclampsia process resolves.

Communication and follow up

Inform the LMC of any woman who has been admitted with severe pre-eclampsia before she is discharged. Postnatal follow-up should be arranged in the appropriate clinic, particularly for women with either early onset (less than 30 weeks) complicated pre-eclampsia or persistent hypertension. This is usually in the high risk maternal fetal medicine clinic and usually by one of the obstetric physicians.
12. Acute management of hypertension

We recommend that the acute management of these women is directly supervised by a registrar or more senior clinician. It should also take into account the background medical history especially the existence of background hypertension.

SBP ≥ 170 and or DBP ≥ 110. If these levels exist for longer than 30 minutes these women should have urgent medical review and be managed in HDU. Recheck BP every 15 minutes. If BP sustained for more than 30 minutes or BP ≥ 180/120 mmHg at any time use the medications listed below.

SBP between 160 and 170 and DBP between 100 and 110. Consider oral antihypertensive therapy using labetalol or slow release nifedipine.

SBP < 160 and DBP < 100. No acute or urgent treatment usually required.

Nifedipine

Given as 5mg capsule – (swallowed and not sublingual or slow release tablet). Repeat doses of 5 - 10mgs every 20 - 30 minutes, up to a maximum of 20mgs may be given if the SBP remains ≥ 170 and or DBP ≥ 110.

If nifedipine controls the blood pressure it can be repeated 6 hourly initially, but may be changed to a slow-release preparation for longer term treatment.

If acceptable blood pressure control is not achieved use labetalol as outlined below. Women whose blood pressure control is of concern should be transferred to HDU or a clinical area with 1:1 midwifery and nursing care.

Blood pressure should be measured every 10 minutes for at least the first half-hour after acute treatment is started as sometimes a marked drop in pressure may occur.

The fetal heart rate should be continuously monitored during stabilisation of severe hypertension as a fetal bradycardia can be precipitated.

Labetalol

Labetalol is contra-indicated in patients with a history of steroid dependant asthma or obstructive airways disease. Oral nifedipine would be the drug of choice in these women. In mild asthma (i.e. defined as not requiring regular or steroid based medication), labetalol may be used with caution and attention paid to the development of bronchospasm.

If the woman can tolerate oral therapy, give an initial 200mg dose of labetalol orally. This can be given immediately before venous access is achieved. A reduction in blood pressure should occur within about 30 minutes. A second oral dose can be given if SBP remains ≥ 170 and or DBP ≥ 110.

If there is no initial response to oral therapy or if it cannot be tolerated, control of blood pressure should be achieved by intravenous labetalol boluses, possibly
followed by a labetalol infusion. This should be done by a doctor who is familiar with the use of IV labetalol and can also stay with the mother to constantly monitor the response. Remember precipitous falls in BP can occur especially in women already on antihypertensive medication.

Initial boluses of labetalol 10-20mg with five minutes delay to assess effect can be followed by larger boluses and if necessary an ongoing infusion. These women (and the foetus if appropriate) must be monitored continuously.

Recommended bolus injection is 20mg (given as 4ml labetalol: 5mg/ml) given slowly over 5 - 10 minutes. This should have an effect after 5 minutes and can be repeated if the SBP remains ≥ 170 and or DBP ≥ 110 mmHg. This can be repeated to a maximum dose of 200mg IV.

Following this a labetalol infusion may be commenced at the discretion of an obstetric physician (see ‘Associated ADHB documents’ section below for labetalol guideline).

13. Anaesthesia and analgesia for women with pre-eclampsia and hypertension

Severe pre-eclampsia is not a contraindication to epidural analgesia providing the platelet count is > 100 x 109/l. All women with proteinuric hypertension should have a platelet count performed on admission to delivery suite.

Hypovolemia is part of the pathophysiology of pre-eclampsia, and careful attention to fluid balance is mandatory, particularly with epidural analgesia. In women with fulminating pre-eclampsia, the platelet count may drop rapidly and need rechecking prior to insertion of an epidural.

All women should be encouraged to have epidural analgesia unless contraindicated. Regional anaesthesia is the method of choice for caesarean section, especially for preterm delivery, unless there are clinical indications for preferring general anaesthesia (GA). Adequate control of blood pressure prior to general anaesthesia is essential for optimal maternal safety.
14. Criteria for transfer to critical care

- Persisting convulsions
- BP > 180/120 despite appropriate doses of labetalol/nifedipine
- Pulmonary oedema with oliguria
- Oliguria with normal CVP, unresponsive to frusemide
- Compromised myocardial function
- Neurological impairment requiring ventilation
- Massive blood loss
- Inadequate staffing levels or experience (medical or midwifery) on HDU
- Other complicating co morbidities

We recommend early discussion with the relevant clinicians on critical care about the ongoing clinical condition of women who may need advanced resuscitation or possible transfer.
15. Postpartum management

Disease progress and treatment

In the immediate postpartum period women who have pre-eclampsia should continue to be monitored for disease resolution. Women who develop multisystem complications prior to delivery usually deteriorate further in the first 48 - 72 hours post partum. There is a physiological rise in BP after delivery and treatment instigated before delivery should probably continue for a minimum of 3 - 4 days. Forty percent of eclampsia occurs post partum however eclampsia is unlikely to present after the fifth postpartum day. In general we recommend that women with pre-eclampsia especially complicated or severe disease stay in hospital for at least 72 hours post partum. Because methyldopa is associated with mood disturbance and involves a multiple dose regime, a postnatal change to nifedipine slow-release 10 - 20mg bd or an ACE inhibitor (usually enalapril) should be considered. Women with known chronic hypertension can be managed with their pre-pregnancy regimen, with appropriate regard to safety in breastfeeding.

New hypertension

Hypertension may arise de novo in the postpartum period in women who did not have hypertension in the antenatal period. This could be a non-specific phenomenon but may also be late onset pre-eclampsia or the unmasking of chronic hypertension. The relevant investigations for pre-eclampsia should be performed. Antihypertensive therapy should be considered if the blood pressure persistently exceeds SBP ≥ 140 - 160 and or DBP ≥ 95 - 100.

Ongoing monitoring and discharge

Blood pressure should be monitored regularly after hospital discharge. Once the BP is ≤ 140/90 anti-hypertensive therapy can be reduced as necessary by the GP. Most women with pregnancy-induced hypertension or pre-eclampsia will no longer require therapy by six weeks postpartum. A six week postnatal visit to the hospital should be arranged for women with persistent hypertension. A discharge summary/letter by the registrar or SMO is mandatory if there are any complicating or unusual features to the pregnancy or management of hypertension. Advice about future pregnancies is also recommended. It is often useful to copy this to the mother.

Standard letter to patient: See the Associated ADHB document section below.

Breastfeeding

In general breastfeeding is strongly recommended in women with hypertension. Treatment with oral anti-hypertensive agents does not preclude breastfeeding. Treatment with ACE inhibitors appears safe during breastfeeding (Hale Drugs in Pregnancy and Lactation, Beardmore, 2008).
Post natal follow up

This should be arranged in the appropriate clinic, usually with the clinician’s responsible for leading antenatal care, particularly for women with atypical or severe disease. The aims of this visit are to ensure adequate control of BP, investigate possible underlying causes and to provide appropriate contraceptive and future pregnancy advice and planning. Diet and lifestyle modifications should also be discussed with appropriate recommendations.

16. What to do before developing an antenatal care plan

Identify the presence of any one of the following factors that predispose women in a given pregnancy to pre-eclampsia (grade B/C):

- First pregnancy
- Previous pre-eclampsia
- ≥ 10 years since last baby
- Age ≥ 40 years
- Body mass index ≥ 35
- Family history of pre-eclampsia (mother or sister)
- Booking diastolic blood pressure ≥ 80 mm Hg
- Proteinuria at booking (≥ + on more than one occasion or ≥ 300 mg/24 hours?)
- Multiple pregnancy
- Underlying medical conditions:
  - Pre-existing hypertension
  - Pre-existing renal disease
  - Pre-existing diabetes
  - Presence of antiphospholipid antibodies

17. What to do after the risk assessment

Offer women a referral before 20 weeks for specialist input to their antenatal care plan if they have one of the following (grade D/good practice point):

- Previous pre-eclampsia
- Multiple pregnancy
- Underlying medical conditions:
  - Pre-existing hypertension or booking diastolic blood pressure ≥ 90 mm Hg
  - Pre-existing renal disease or booking proteinuria (≥ + on more than one occasion or ≥ 300 mg/24 hours?)
  - Pre-existing diabetes
  - Presence of antiphospholipid antibodies
  - Any two other factors from what to do before developing an antenatal care plan
18. Supporting evidence

- Bodnar er al. Am J Epidemiol 2006; Periconceptional Multivitamin use reduces risk of preeclampsia. 164,470-7
- Duley L, Henderson-Smart DJ, Meger S. Drugs for treatment of very high blood pressure in pregnancy. Cochrane Database of Systematic Reviews 2006 Jul 19;3: CD001449
- Errol R Norwitz and John T Repke. Management of pre-eclampsia Up to Date version 16.2 May 2008
- Hale, T. Drugs in Pregnancy and Lactation, Beardmore, 2008
- Poston et al. Vitamin C and Vitamin E in pregnant women at risk of preeclampsia (VIP Trial): Randomised placebo controlled trial. Lancet 2006; 367,1145-54
- Wen et al. Folic acid supplementation in early second trimester and risk of preeclampsia. AMJOG 2008; 198,45e1-45e7
- Management of hypertension in pregnancy. Phyllis August Up to Date version 16.2 May 2008
- Pre-eclampsia study group recommendations RCOG press 2003
19. Associated ADHB documents

- Admission - Day Assessment Unit
- Labetalol MAG
- Magnesium Sulphate for Preeclampsia and for Neuroprotection in Pre-Term Births <30 weeks
- Referral - Maternal Fetal Medicine
- Standard letter to patient

20. Disclaimer

No guideline can cover all variations required for specific circumstances. It is the responsibility of the health care practitioners using this ADHB guideline to adapt it for safe use within their own institution, recognise the need for specialist help, and call for it without delay, when an individual patient falls outside of the boundaries of this guideline.

21. Corrections and amendments

The next scheduled review of this document is as per the document classification table (page 1). However, if the reader notices any errors or believes that the document should be reviewed before the scheduled date, they should contact the owner or the Clinical Policy Advisor without delay.